NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
Clinical Trials
20 trialsNCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05904457 2023-06-15
BRISK
Asan Medical Center
Phase 2 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02714530 2021-03-30
ThoRaT
Oslo University Hospital
Phase 2 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT00497224 2019-05-30
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 2 Completed
NCT01518621 2019-03-13
RadEr
Oslo University Hospital
Phase 2 Terminated
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT03389256 2018-01-03
Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT00369512 2017-05-30
RAD0503
University of Alabama at Birmingham
Phase 2 Completed
NCT00841035 2017-05-19
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
University of Alabama at Birmingham
Phase 2 Terminated
NCT00491816 2017-01-19
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
University of Kansas Medical Center
Phase 2 Unknown
NCT00336700 2016-09-19
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT00585377 2015-09-24
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
University of Utah
Phase 2 Completed
NCT00109265 2015-07-02
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy
Genentech, Inc.
Phase 2 Completed
NCT00642746 2014-09-26
Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01565538 2014-09-15
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Sun Yat-sen University
Phase 2 Completed
NCT02034097 2014-05-19
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Withdrawn